<DOC>
	<DOCNO>NCT00016991</DOCNO>
	<brief_summary>RATIONALE : Biological therapy ZD 1839 may interfere growth tumor cell slow growth glioblastoma multiforme . PURPOSE : Phase II trial study effectiveness ZD 1839 treat patient glioblastoma multiforme first relapse .</brief_summary>
	<brief_title>ZD 1839 Treating Patients With Glioblastoma Multiforme First Relapse</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity ZD 1839 patient glioblastoma multiforme first relapse . - Determine pharmacokinetics toxicity drug patient . - Assess relationship epidermal growth factor receptor status patient activity drug . OUTLINE : Patients receive oral ZD 1839 daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow least 6 month . PROJECTED ACCRUAL : A total 53 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme first relapse PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 12 week Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine le 1.5 time ULN Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No prior allergic reaction compound similar chemical biologic composition ZD 1839 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Ocular inflammation must fully treat study entry PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Must stable dose steroid least 1 week Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : At least 1 week since prior surgery Other : No concurrent investigational agent No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIV No concurrent enzymeinducing anticonvulsant drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>